1Philosophy of cooperation in clinical trials for pediatric drugs in the United States and its inspirations on ChinaCHEN Yong-fa, SHI Ying857-860,8842Evaluation of technological innovation capability in the pharmaceutical industry in the eastern ChinaCHU Shu-zhen, ZHANG Su-rong861-864,8783Translational medicine: solution to increase R&D productivityFrank Jiang865-8704Clinical trial status and trends from quality management perspectiveLI Qing-hong, CHEN Jing, ZHANG Ping, ZHOU Li-ping871-8785Current status and trend of clinical data management at electronization timeDENG Ya-zhong, YU Jia, LIU Chuan, LIU Zong-fan879-8846Considerations on project management of clinical trials in ChinaFANG Fang885-888,8957Statistical methods for clinical trials in oncologyYIN Yue, ZHANG Hui, QU Peng889-8958Research and analysis of CMC requirements for generic PEGylated liposomal doxorubicinZHANG Ning896-900,9119The structural characterization of low molecular weight heparinZHANG Zhen901-905,93910Comments on the development and assessment of the drug impurities and substances related to recombinant monoclonal antibodiesWEI Wei, LUO Jian-hui, YIN Hong-zhang, XIANG Jin-zhong906-91111Overview of the vaccine quality and regulation requirements in ChinaGAO En-ming, LI Min, YIN Hong-zhang, LUO Jian-hui912-91412Theory and methodology of enrichment strategies and its application in new drug developmentYANG Zhi-min, LI Ning, GAO Chen-yan, CHEN Xiao-yuan, ZHANG Jie915-920,94713Application of "quality by design" in the formulation and process research of generic injectionsJIANG Yu, YANG Jian-hong, WANG Ya-min921-924,95414Technical requirements and related guidelines of the nanodrugs in FDA and EMAHE WU, YANG Jian-hong, WANG Hai-xue, LI Xue-ming925-93115Key points of the changes of FDA guidance on BA/BE studies in INDs/NDAsLI Li, ZHANG Yu-hu932-93516Interpretation of the summary sheet of main research information in the form CTD (drug substance)KANG Jian-lei, HE Wu, XU Zhen-yu, LI Xue-mei936-93917Interpretation of the guideline of compatibility study of pharmaceutical products and packaging materials——the assessment of experimental dataMA Yu-nan, MA Lei, JIANG Yu940-94318Discussion of key issues on the origin change of APIs used in pharmaceutical preparationsSHI Ji-feng, WANG Ya-min, LIU Lu944-94719A new concept of pharmaceutical management system: quality-by-design (QbD)WANG Ming-juan, HU Xiao-ru, DAI Zhong, MA Shuang-cheng948-95420Targeting B-RAF mutation for cancer therapyYUAN Xi, DU Rong, WEI Jing, WEI Min, LUO Lü-song955-961 